AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3316059 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m 1099 (50 mg with breakfast and dinner)
Number of subjects: 7
Study 3316059 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 7
Study 29511011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous drinking (measured by AUDIT‐C)
Number of subjects: 871
Study 29511011 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-hazardous drinkers)
Number of subjects: 871
Study 26873537 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ERCP in patients ≥80 years
Number of subjects: 624
Study 26873537 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ERCP in patients <65 years
Number of subjects: 624
Study 25464679 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training
Number of subjects: 0
Study 25464679 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise (PE) group
Number of subjects: 0
Study 25464679 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after yoga training
Number of subjects: 0
Study 22727870 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 55
Study 22727870 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched children prior to treatment)
Number of subjects: 55
Study 22727870 — intervention group
Group type: COMPARATOR
Intervention: Age-matched normograms
Number of subjects: 55
Study 20706875 — intervention group
Group type: COMPARATOR
Intervention: Placebo adherence (≥75% of prescribed study medication)
Number of subjects: 0
Study 18706159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary surfactants (PS) combined with continuous distending pressure (CDP)
Number of subjects: 90
Study 18706159 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary surfactants (PS) alone
Number of subjects: 90
Study 18706159 — intervention group
Group type: COMPARATOR
Intervention: Continuous distending pressure (CDP) alone
Number of subjects: 90
Study 15919462 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB) induction and daily mycophenolate mofetil (MMF; 2 g) with steroids (20 mg prednisone)
Number of subjects: 51
Study 15919462 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy with tacrolimus, MMF, and prednisone
Number of subjects: 51
Study 15919462 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB) treatment
Number of subjects: 51
Study 15919462 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rate of immediate function
Number of subjects: 51
Study 15215814 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (15 to 30 mg/d; n = 48)
Number of subjects: 96
Study 15215814 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg/d; n = 48)
Number of subjects: 96
Study 15215814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACE inhibitors
Number of subjects: 96
Study 11770424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasinizid (group A)
Number of subjects: 115
Study 11770424 — intervention group
Group type: COMPARATOR
Intervention: HP regimen (group B1)
Number of subjects: 115
Study 11770424 — intervention group
Group type: COMPARATOR
Intervention: SH regimen (group B2)
Number of subjects: 115
Study 9441266 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antibiotic + oral ciprofloxacin sequential therapy (group B)
Number of subjects: 298
Study 9441266 — intervention group
Group type: COMPARATOR
Intervention: Parenteral antibiotics only (group A)
Number of subjects: 298
Study 8356584 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA high dose
Number of subjects: 1347
Study 8356584 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA medium dose
Number of subjects: 1347
Study 8356584 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA low dose
Number of subjects: 1347
Study 8356584 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejection episodes
Number of subjects: 1347
Study 3621768 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaglute 324mg
Number of subjects: 12
Study 3621768 — intervention group
Group type: EXPERIMENTAL
Intervention: Biquin Durules 250mg
Number of subjects: 12
Study 3621768 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidex 300mg
Number of subjects: 12
Study 31691981 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 0
Study 29882279 — intervention group
Group type: EXPERIMENTAL
Intervention: R-THP-COP
Number of subjects: 81
Study 29882279 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 81
Study 29154068 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga home-exercise (10min daily)
Number of subjects: 38
Study 29154068 — intervention group
Group type: COMPARATOR
Intervention: Relaxation exercises only (control group)
Number of subjects: 38
Study 26193126 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (immediate ART initiation)
Number of subjects: 2056
Study 26193126 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid Preventive Therapy (IPT)
Number of subjects: 2056
Study 26193126 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART (ART initiation according to WHO criteria)
Number of subjects: 2056
Study 26193126 — intervention group
Group type: COMPARATOR
Intervention: No IPT
Number of subjects: 2056
Study 23866782 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical extraction during the middle of the menstrual cycle
Number of subjects: 145
Study 23866782 — intervention group
Group type: COMPARATOR
Intervention: Surgical extraction during the menstrual period
Number of subjects: 145
Study 23866782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) users
Number of subjects: 145
Study 23866782 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of oral contraceptives
Number of subjects: 145
Study 21944048 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CT volumetry after 14 days of neoadjuvant chemoradiotherapy
Number of subjects: 39
Study 21944048 — intervention group
Group type: COMPARATOR
Intervention: Histopathological response
Number of subjects: 39
Study 18491582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril monotherapy
Number of subjects: 42
Study 18491582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine monotherapy
Number of subjects: 42
Study 18491582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Lisinopril and Amlodipine
Number of subjects: 42
Study 17699287 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 206
Study 17699287 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 206
Study 14575344 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonology first condition (12-week phonological intervention followed by 12 weeks of morphosyntax)
Number of subjects: 47
Study 14575344 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphosyntax first condition (12-week morphosyntax intervention followed by 12 weeks of phonology)
Number of subjects: 47
Study 14575344 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating condition (phonology and morphosyntax goals alternating weekly)
Number of subjects: 47
Study 14575344 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous condition (phonological and morphosyntactic goals each session)
Number of subjects: 47
Study 14575344 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 47
Study 11221291 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine (10 or 20 mg/day)
Number of subjects: 106
Study 11221291 — intervention group
Group type: COMPARATOR
Intervention: Barnidipine (20 mg/day)
Number of subjects: 106
Study 8706770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 1.0 mg b.i.d. for 3.5 days (seven doses)
Number of subjects: 24
Study 8706770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 0.8 mg b.i.d. for 3.5 days (seven doses)
Number of subjects: 24
Study 8706770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18415635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion at a dose of 1.5 mg/kg body weight (over 10 min) 30 min before surgery, followed by 2 mg/kg body weight per h over 6 h and 0.5 mg/kg body weight per h for another 18 h
Number of subjects: 40
Study 18415635 — intervention group
Group type: COMPARATOR
Intervention: Control group received identical volumes of 0.9% NaCl solution
Number of subjects: 40
Study 18415635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 40
Study 3931273 — intervention group
Group type: EXPERIMENTAL
Intervention: MAA (Modified Amino Acid formulas)
Number of subjects: 18
Study 3931273 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acids
Number of subjects: 18
Study 31924249 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized SMAs led by a health educator with a set order of TTIM topics
Number of subjects: 1440
Study 31924249 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven SMAs delivered collaboratively by a multidisciplinary care team
Number of subjects: 1440
Study 30559105 — intervention group
Group type: COMPARATOR
Intervention: Molidustat (25, 50, and 75 mg once daily; 25 and 50 mg twice daily)
Number of subjects: 444
Study 30559105 — intervention group
Group type: COMPARATOR
Intervention: Molidustat (variable doses after switching from darbepoetin)
Number of subjects: 444
Study 30559105 — intervention group
Group type: COMPARATOR
Intervention: Molidustat (75 and 150 mg after switching from epoetin)
Number of subjects: 444
Study 27183299 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH XR-ODT (optimized dose)
Number of subjects: 87
Study 27183299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 25838249 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline with behavioral counseling
Number of subjects: 187
Study 25838249 — intervention group
Group type: COMPARATOR
Intervention: Unassisted MILD patient
Number of subjects: 187
Study 23685743 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardiac computed tomographic angiography (CCTA)
Number of subjects: 1000
Study 23685743 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency department evaluation
Number of subjects: 1000
Study 21131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 63
Study 21131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 63
Study 21131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) and (40 mg/day)
Number of subjects: 63
Study 21131223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 19187079 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux 2.5 mg once-weekly subcutaneously
Number of subjects: 2064
Study 19187079 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux 1.5 mg for patients with severe renal insufficiency
Number of subjects: 2064
Study 17105798 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) - 150 mg of testosterone enanthate intramuscularly every 2 weeks for 6 months
Number of subjects: 44
Study 17105798 — intervention group
Group type: COMPARATOR
Intervention: Placebo - matching placebo intramuscularly every 2 weeks for 6 months
Number of subjects: 44
Study 15507054 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered showering
Number of subjects: 73
Study 15507054 — intervention group
Group type: EXPERIMENTAL
Intervention: Towel bath
Number of subjects: 73
Study 15507054 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 73
Study 11702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference tissue‐based linear least squares (RLS) analysis using [(11)C]MP4A PET data.
Number of subjects: 38
Study 11702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear least squares (NLS) analysis using [(11)C]MP4A PET data.
Number of subjects: 38
Study 11702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape analysis (another method of [(11)C]MP4A kinetic analysis without blood sampling).
Number of subjects: 38
Study 11702050 — intervention group
Group type: COMPARATOR
Intervention: Reference tissue‐based linear least squares (RLS) analysis.
Number of subjects: 38
Study 9393520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodynamic rheolytic thrombectomy device
Number of subjects: 50
Study 7951476 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking four 0.8 mg nicotine cigarettes
Number of subjects: 10
Study 7951476 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of 200 mg of caffeine
Number of subjects: 10
Study 7951476 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking four 0.8 mg cigarettes and ingesting 200 mg of caffeine
Number of subjects: 10
Study 7951476 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of caffeine (in non-smoking controls)
Number of subjects: 10
Study 2889518 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg bid
Number of subjects: 115
Study 2889518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care (attended a clinic)
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of ART within 3 months
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care associated with HIV-status disclosure intentions
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care associated with treatment readiness
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care negatively associated with good health
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care negatively associated with weekly alcohol consumption
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care negatively associated with internalised stigma
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stigma
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to ART initiation
Number of subjects: 86
Study 30635862 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivating factors for ART initiation
Number of subjects: 86
Study 26559709 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 1487
Study 26559709 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1487
Study 26559709 — intervention group
Group type: COMPARATOR
Intervention: Control (usual programs)
Number of subjects: 1487
Study 25385166 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised core strengthening programme
Number of subjects: 78
Study 25385166 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based core strengthening programme
Number of subjects: 78
Study 25385166 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 24379274 — intervention group
Group type: COMPARATOR
Intervention: Chronic ambulatory peritoneal dialysis (CAPD) patients
Number of subjects: 25
Study 24379274 — intervention group
Group type: COMPARATOR
Intervention: Peritoneally dialyzed (PD) patients
Number of subjects: 25
Study 24379274 — intervention group
Group type: COMPARATOR
Intervention: Patients with hyperglycemia
Number of subjects: 25
Study 21865768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glycerophosphate in TPN emulsion
Number of subjects: 10
Study 21865768 — intervention group
Group type: COMPARATOR
Intervention: Pure sodium glycerophosphate formulation (reference)
Number of subjects: 10
Study 19624359 — intervention group
Group type: EXPERIMENTAL
Intervention: PediSedate
Number of subjects: 36
Study 19624359 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 36
Study 16750984 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with asthma
Number of subjects: 2208
Study 16750984 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects without asthma from index families
Number of subjects: 2208
Study 16750984 — intervention group
Group type: COMPARATOR
Intervention: General population controls
Number of subjects: 2208
Study 15570289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone resorption markers (BRM)
Number of subjects: 176
Study 15570289 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal telopeptide of collagen I
Number of subjects: 176
Study 15570289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone formation markers (BFM)
Number of subjects: 176
Study 15570289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios BRM/BFM containing bAP
Number of subjects: 176
Study 12767950 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Number of subjects: 0
Study 12767950 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 9553645 — intervention group
Group type: COMPARATOR
Intervention: Heparin/Aspirin (H/A) alone
Number of subjects: 82
Study 9553645 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin/Aspirin in combination with IVIg
Number of subjects: 82
Study 9055693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline solution conditioning for 5 minutes
Number of subjects: 10
Study 9055693 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline solution rinse
Number of subjects: 10
Study 2244558 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 27
Study 2244558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 359904 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 0.25% and 0.5%
Number of subjects: 40
Study 359904 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 1%, 2%, and 4%
Number of subjects: 40
Study 359904 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol alone or in combination with a topical cholinergic agent or/and a systemic carbonic anhydrase inhibitor
Number of subjects: 40
Study 30758163 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMP Test (0.27 W·sec⁻¹)
Number of subjects: 57
Study 30758163 — intervention group
Group type: COMPARATOR
Intervention: STEP Test (50W·3min⁻¹)
Number of subjects: 57
Study 28917374 — intervention group
Group type: EXPERIMENTAL
Intervention: Bell pepper juice (100 ml, twice/day) with integrated approach of yoga therapy (IAYT)
Number of subjects: 50
Study 28917374 — intervention group
Group type: COMPARATOR
Intervention: Integrated approach of yoga therapy (IAYT)
Number of subjects: 50
Study 26686275 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 0
Study 26686275 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance pressure
Number of subjects: 0
Study 26686275 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and Performance pressure
Number of subjects: 0
Study 24482441 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (n = 42)
Number of subjects: 80
Study 24482441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 80
Study 21953572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg single dose) in subjects with normal renal function
Number of subjects: 16
Study 21953572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg single dose) in subjects with severe renal impairment
Number of subjects: 16
Study 21953572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg single dose) in subjects receiving hemodialysis
Number of subjects: 16
Study 19025719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil diet (vegetables low in beta-carotene with supplemental beta-carotene in salad dressing oil)
Number of subjects: 24
Study 19025719 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet (vegetables and fruits high in beta-carotene)
Number of subjects: 24
Study 19025719 — intervention group
Group type: COMPARATOR
Intervention: Comparison between oil diet and mixed diet
Number of subjects: 24
Study 17563408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (10mg/d)
Number of subjects: 35
Study 15217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum IGF-I levels
Number of subjects: 253
Study 15217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum IGFBP-3 levels
Number of subjects: 253
Study 15217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum IGFBP-3 levels
Number of subjects: 253
Study 15217929 — intervention group
Group type: COMPARATOR
Intervention: Lower IGF-I levels
Number of subjects: 253
Study 15217929 — intervention group
Group type: COMPARATOR
Intervention: Lower IGFBP-3 levels
Number of subjects: 253
Study 15217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGF-I levels
Number of subjects: 253
Study 15217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGFBP-3 levels
Number of subjects: 253
Study 11738689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray containing alpha-haemolytic streptococci (AHS), administered once daily for 4 months.
Number of subjects: 43
Study 11738689 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray, administered once daily for 4 months.
Number of subjects: 43
Study 9718538 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (40 minutes of jogging and 20 minutes of gymnastics three times a week for 1 year)
Number of subjects: 83
Study 9718538 — intervention group
Group type: COMPARATOR
Intervention: Exercise program (40 minutes of jogging and 20 minutes of gymnastics three times a week for 6 months)
Number of subjects: 83
Study 9718538 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (after 6 months, introduced to exercise classes with wrist weights of 0.8 kg on each arm)
Number of subjects: 83
Study 9718538 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (after 6 months)
Number of subjects: 83
Study 7664364 — intervention group
Group type: EXPERIMENTAL
Intervention: New method using a guide wire for endotracheal tube replacement
Number of subjects: 16
Study 7664364 — intervention group
Group type: COMPARATOR
Intervention: Old method of changing endotracheal tubes
Number of subjects: 16